| Market Overview
The global artificial cornea and corneal implant market was valued at USD 468.85 Million in 2024 and is forecasted to reach USD 831.98 Million by 2033, growing at a CAGR of 6.25% during 2025-2033. Growth is driven by increasing prevalence of corneal infections, expanding healthcare infrastructure, and rising demand for corneal transplantation. North America leads with a 50.5% market share. Study Assumption Years
• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033 Artificial Cornea and Corneal Implant Market Key Takeaways
• Current Market Size: USD 468.85 Million in 2024
• CAGR: 6.25% (2025-2033)
• Forecast Period: 2025-2033
• North America holds 50.5% market share in 2024.
• Human cornea segment dominates due to superior biocompatibility.
• Penetrating keratoplasty is the leading transplant type.
• Fuchs' dystrophy holds 52.5% disease indication share.
• Hospitals lead with 57.5% market share in 2024. Request for sample copy of this report:
https://www.imarcgroup.com/artificial-cornea-corneal-implant-market/requestsample Market Growth Factors
• Rising incidence of corneal infections and eye disorders fuels demand for artificial corneas and implants. Approximately 6 million people globally suffer from corneal opacity, a major cause of blindness.
• Expansion of healthcare infrastructure, including hospitals, eye clinics, and assisted living centers, increases access to corneal treatments.
• Digital device overuse has resulted in more vision issues among younger populations, contributing to demand growth.
• Aging populations worldwide require full-thickness corneal transplants due to degenerative eye diseases.
• Increased healthcare expenditure and government initiatives support greater availability of advanced corneal treatments. The U.S. CDC allocated USD 6.5 million for vision programs in FY2023, including a USD 1 million increase from FY2022.
• By 2050, an estimated 895 million individuals may suffer from distant vision impairment, with 61 million blind, increasing reliance on artificial corneas as dependable alternatives for patients unsuitable for donor tissues. Market Segmentation
Type:
• Human Cornea: Dominates due to high biocompatibility and effective restoration of vision, with reduced complication risks.
• Artificial Cornea Transplant Type:
• Penetrating Keratoplasty: Largest segment in 2024; used to treat serious corneal disorders through full-thickness transplantation.
• Endothelial Keratoplasty
• Anterior Lamellar Keratoplasty
• Keratoprosthesis Disease Indication:
• Fuchs' Dystrophy: Holds 52.5% market share in 2024; common among aging populations and effectively treated with corneal transplants.
• Fungal Keratitis
• Keratoconus
• Others End User:
• Hospitals: Largest segment at 57.5% share in 2024, supported by advanced surgical infrastructure and postoperative care.
• Ambulatory Surgical Centers
• Specialty Clinics By Region:
• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa Regional Insights
North America leads with a 50.5% market share due to high prevalence of corneal disorders, advanced healthcare systems, and strong investments in research and surgical technology. The United States drives regional growth with 90.20% share, supported by a large patient base, rising geriatric population, and strong innovations in transplantation and implant technology. Recent Developments & News
• October 2024: Iran's Ophthalmology Association successfully deployed locally produced artificial corneas for stem cell degeneration treatments.
• September 2024: Aurion Biotech launched Vyznova® (neltependocel) in Japan, the first approved cell therapy for corneal endothelial disease.
• August 2024: Kerato Ltd partnered with University of Montreal on an in-situ gelling treatment using stromal cells and synthetic matrix to reduce transplant need.
• June 2024: CorneaGen introduced Corneal Tissue Addition for Keratoplasty (CTAK) with custom gamma-irradiated corneal segments.
• January 2024: LV Prasad Eye Institute received a 20-year patent for a new stem cell-based corneal regeneration therapy. Key Players
• AJL Ophthalmic S.A.
• CorNeat Vision
• Eye Care of San Diego
• EyeYon Medical
• KeraMed, Inc
• LinkoCare Life Sciences AB
• Lions World Vision Institute
• LJ Eye Institute
• Lv Prasad Eye Institute Customization Note
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization. Request for Customization: https://www.imarcgroup.com/request?type=report&id=4961&flag=E About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research. Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302 | 